| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 25.31B | — |
| Operating expense | — | — |
| Net income | 5.53B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, JNJ returned +54.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +32.0% |
| 1 year | +54.5% |
| 5 years | +78.6% |
| 10 years | +195.7% |
| All-time high | $270.24 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in JNJ would be worth today ›Yes. Johnson & Johnson paid 4 dividends over the past 12 months. The most recent was $1.34 per share on May 26, 2026. The dividend yield is 1.98%.
Johnson & Johnson stock trades on NYSE under the ticker symbol JNJ.
Johnson & Johnson is part of the Healthcare sector.
Johnson & Johnson has a market cap of 651.25B USD, based on the latest quote.
Johnson & Johnson is scheduled to report earnings on Oct 13, 2026.
Johnson & Johnson is a healthcare company founded in 1886 that develops, manufactures and sells prescription medicines and medical devices. Its Innovative Medicine segment covers treatments in areas such as immunology, oncology, neuroscience and infectious disease, sold mainly to wholesalers, hospitals and health systems. Its MedTech segment supplies products used in surgery, orthopedics, cardiovascular care and vision care, including surgical instruments, joint implants and Acuvue contact lenses. The company's former consumer health business, home to brands such as Tylenol and Band-Aid, was separated into Kenvue in 2023, leaving Johnson & Johnson focused on pharmaceuticals and medical technology. It sells its products in markets around the world and reinvests in research and development across both segments.
